MedTrace Logo

Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00826163 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-09-11

No results posted yet for this study

Summary

We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response

Conditions

Interventions

DRUG

Budesonide

Inhaled budesonide 400 mcg twice a day for 2 weeks

Sponsors & Collaborators

  • National Science and Technology Development Agency, Thailand

    collaborator OTHER_GOV

  • Mahidol University

    lead OTHER

Principal Investigators

  • Kittipong Maneechotesuwan, MD, PhD · Mahidol University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • Thailand

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826163 on ClinicalTrials.gov